Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Fitusiran (ALN-AT3) Phase 1 Open Label Extension study initial data expected in late 2016

Source Link:: http://investors.alnylam.com/releasedetail.cfm?ReleaseID=949685

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ALNY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on 7.25.16: Alnylam plans to report additional data from fitusiran studies in late 2016. These data are expected to include additional results from Part D of the ongoing Phase 1 study and initial results from the Phase 1/2 open-label extension (OLE) study.

http://investors.aln...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 03, 2016

Occurred Source:

http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002502

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Fitusiran, Aln-at3, Antithrombin, Hemophilia, Rare Bleeding Disorders, Phase 1, Open Label Extension